Skip to main content
Figure 2 | Respiratory Research

Figure 2

From: A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids

Figure 2

Peak FEV 1(0–3h) and trough FEV 1 responses after 4 weeks of treatment (full analysis set). Adjusted for ‘treatment’, ‘period’, ‘patient’ and ‘baseline’. *p < 0.05; ***p < 0.001 versus placebo Respimat®. FEV1, forced expiratory volume in 1 second; peak FEV1(0–3h), peak forced expiratory volume in 1 second within 3 hours post-dosing.

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us